Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $3.46 billion
- Book Value:
- Revenue TTM:
- $344.39 million
- Operating Margin TTM:
- Gross Profit TTM:
- $203.07 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Certara Inc had its IPO on 2020-12-11 under the ticker symbol CERT.
The company operates in the Healthcare sector and Health Information Services industry. Certara Inc has a staff strength of 1,150 employees.
Shares of Certara Inc opened at $21.54 at the start of the last trading session i.e. 2023-06-02.
The stocks traded within a range of $21.28 - $21.91, and closed at $21.7.
This is a +1.83% increase from the previous day's closing price.
A total volume of 901,556 shares were traded at the close of the day’s session.
In the last one week, shares of Certara Inc have increased by +1.64%.
Certara Inc's Key Ratios
Certara Inc has a market cap of $3.46 billion, indicating a price to book ratio of 2.4654 and a price to sales ratio of 8.0733.
In the last 12-months Certara Inc’s revenue was $344.39 million with a gross profit of $203.07 million and an EBITDA of $89.12 million. The EBITDA ratio measures Certara Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Certara Inc’s operating margin was 10.47% while its return on assets stood at 1.47% with a return of equity of 1.3%.
In Q1, Certara Inc’s quarterly earnings growth was a negative -14.1% while revenue growth was a positive 10.7%.
Certara Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $0.09 per share while it has a forward price to earnings multiple of 33.4448 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Certara Inc’s profitability.
Certara Inc stock is trading at a EV to sales ratio of 8.3067 and a EV to EBITDA ratio of 32.5365. Its price to sales ratio in the trailing 12-months stood at 8.0733.
Certara Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.57 billion
- Total Liabilities
- $93.82 million
- Operating Cash Flow
- Capital Expenditure
- $2.73 million
- Dividend Payout Ratio
Certara Inc ended 2023 with $1.57 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.57 billion while shareholder equity stood at $1.09 billion.
Certara Inc ended 2023 with $0 in deferred long-term liabilities, $93.82 million in other current liabilities, 1601000.00 in common stock, $-59515000.00 in retained earnings and $718.84 million in goodwill. Its cash balance stood at $244.14 million and cash and short-term investments were $244.14 million. The company’s total short-term debt was $7,828,000 while long-term debt stood at $289.55 million.
Certara Inc’s total current assets stands at $348.25 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $82.40 million compared to accounts payable of $4.33 million and inventory worth $0.
In 2023, Certara Inc's operating cash flow was $-2731000.00 while its capital expenditure stood at $2.73 million.
Comparatively, Certara Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Certara Inc stock is currently trading at $21.7 per share. It touched a 52-week high of $24.96 and a 52-week low of $24.96. Analysts tracking the stock have a 12-month average target price of $24.83.
Its 50-day moving average was $22.66 and 200-day moving average was $17.94 The short ratio stood at 7.47 indicating a short percent outstanding of 0%.
Around 327.4% of the company’s stock are held by insiders while 8980% are held by institutions.
Frequently Asked Questions About Certara Inc
Similar Industry Stocks (Health Information Services)
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers’ new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Australia, Canada, China, France, Germany, India, Italy, Japan, Luxembourg, the Netherlands, the Philippines, Poland, Portugal, Spain, Switzerland, and the United Kingdom. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.